IP Verse

Use Of A Ginkgo Biloba Leaf Extract - EP2072054

The patent EP2072054 was granted to DR Willmar Schwabe on Nov 7, 2018. The application was originally filed on Dec 21, 2007 under application number EP07024973A. The patent is currently recorded with a legal status of "Revoked".

EP2072054

DR WILLMAR SCHWABE
Application Number
EP07024973A
Filing Date
Dec 21, 2007
Status
Revoked
Nov 1, 2024
Grant Date
Nov 7, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

KRANZLEJul 29, 2019PFENNINGADMISSIBLE
MIDAS PHARMANov 8, 2018TER MEER STEINMEISTER & PARTNERADMISSIBLE
STADA ARZNEIMITTELNov 8, 2018TER MEER STEINMEISTER & PARTNERADMISSIBLE
MAX ZELLER SOHNENov 8, 2018KASCHEWITHDRAWN

Patent Citations (12) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0431535
DESCRIPTIONWO2006117169
DESCRIPTIONWO2006117170
OPPOSITIONWO03047511
OPPOSITIONWO2006117169
SEARCHEP1559430
SEARCHWO0213841
SEARCHWO2006009373
SEARCHWO2006117168
SEARCHWO2006117169
SEARCHWO2006117170
SEARCHWO2006117171

Non-Patent Literature (NPL) Citations (81) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- DEJONG R; OSTERLUND OW; ROY GW, "Measurement of Quality-of-Life changes in patients with Alzheimer's disease", CLINICAL THERAPEUTICS, (1989), vol. 11, pages 545 - 554
DESCRIPTION- SCHNEIDER LS ET AL., "Alzheimer's Disease Cooperative Study. Validity and Reliability of the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change", ALZHEIMER DISEASE AND ASSOCIATED DISORDERS, (1997), vol. 11, no. 2, pages S22 - S32
DESCRIPTION- SCHNEIDER LS ET AL., "A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type", CURRENT ALZHEIMER RESEARCH, (2005), vol. 2, pages 541 - 551, XP055306045
DESCRIPTION- SMITH SC ET AL., "Measurement of health-related quality of life for people with dementia: development of anew instrument (DEMQOL) and an evaluation of current methodology", HEALTH TECHNOLOGY ASSESSMENT, (2005), vol. 9, page 10
DESCRIPTION- WALACH H ET AL., "The therapeutic effect of clinical trials: understanding placebo response rates in clinical trials - A secondary analysis", BMC MEDICAL RESEARCH METHODOLOGY, (2005), vol. 5, doi:doi:10.1186/1471-2288-5-26, page 26, XP021003534
EXAMINATION- A. POPA, "Ginkgo Biloba and Memory", PHARMACOTHERAPY UPDATE, (200209), vol. v, no. v
EXAMINATION- BARNES ET AL, "Memory complaints are related to Alzheimer disease pathology in older persons", NEUROLOGY, (2009), vol. 67, pages 1581 - 1885
EXAMINATION- B. GRASS-KAPANKE ET AL, "Effects of Ginkgo biloba special extract EGb 761 in very mild cognitive impairment (vMCI)", NEUROSCIENCE AND MEDICINE, (2011), vol. 2, pages 48 - 56
EXAMINATION- Chapter 1, Marketing Authorisation, Notice to Applicants,Procedures for marketing authorisation, European Commission, (201511), vol. 2A
EXAMINATION- European Medicines Agency, European Union herbal monograph on Ginkgo biloba L.folium
EXAMINATION- H. HERRSCHAFT ET AL, "Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg", JPOURNALOF PSYCHIATRIC RESEARCH, (2012), vol. 26, pages 716 - 723
EXAMINATION- JESSEN ET AL, "Prediction of dementia by subjective memory impairment", ARCHIVES OF GENERAL PSYCHIATRY, (2010), vol. 67, pages 414 - 422
EXAMINATION- L. S. SCHNEIDER ET AL., CURRENT ALZHEIMER RESEARCH, (2005), vol. 2, pages 541 - 551
EXAMINATION- O. NAPRYEYENKO ET AL, DRUG RESEARCH, (2007), vol. 57, no. 1, pages 4 - 11
EXAMINATION- Phylis A. Balch, Prescription for Herbal Healing, USA, Avery, (2002), pages 183 - 186
EXAMINATION- Pschyrembel Klinisches Wörterbuch, Walter de Gruyter, (1990), page 335
EXAMINATION- REISBERG ET AL, "Outcome over sven years of healthy adults with and without subjective cognitive impairment", ALZEHEIMER'S AND DEMENTIA, (2010), vol. 6, pages 11 - 24
EXAMINATION- R. IHL ET AL, "Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features. a randomized controlled trial", INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, (2011), vol. 26, pages 1186 - 1194
EXAMINATION- S. GAUTHIER ET AL, CLINICAL INVESTIGATIONS IN AGING, (2014), vol. 9, pages 2065 - 2077
EXAMINATION- SI GAVRILOVA ET AL, "Efficy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: A randomized, placebo-controlled, double-blind, multi-center trial", INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, (2014), vol. 29, pages 1087 - 1095
EXAMINATION- S. KANOWSKI ET AL, "Gingko biloba Extract EGb 761 in Dementia: Intent to treat Analyses of a 24-week, Multi-center, Double-blind, Placebo-controlled, Randomized Trial", PHARMACOPSYCHIATRY, (2003), vol. 36, pages 297 - 303
EXAMINATION- T. M. ITIL ET AL, AMERICAN JOURNAL OF THERAPEUTICS, (1996), vol. 3, pages 63 - 73
OPPOSITION- "[A05-19B] Ginkgohaltige Präparate bei Alzheimer Demenz", Dokumentation und Würdigung der Stellungnahmen zum Berichtsplan Version 1.0, (20071001), pages 51 - 64, XP055527560
OPPOSITION- "[A05-19B] Ginkgo Präparate bei Alzheimer Demenz", Dokumentation und Würdigung der Stellungnahmen zum Berichtsplan Version 1.0, (20071001), pages 51 - 64, XP055527560
OPPOSITION- ANDREEA POPA, "Ginkgo Biloba and Memory", Pharmacotherapy, (20020000), XP003025476
OPPOSITION- Andreea Popa, "Ginkgo Biloba and Memory", Pharmacotherapy, (20020900), XP003025476
OPPOSITION- Anonymous, "Monograph: Gingko Biloba", Alternative Medicine Review, (19980000), vol. 3, no. 1, pages 54 - 57, XP055628971
OPPOSITION- Anonymous, "Monographie: Trockenextrakt (35-67:1) aus Ginkgo-biloba-Blättern, extrahiert mit Aceton-Wasser", (19940719), XP055527507
OPPOSITION- DEKOSKY et al., "Ginkgo biloba for prevention of dementia - a randomized controlled trial", JAMA, (20080000), vol. 300, no. 19, pages 2253 - 2262, XP055527587
OPPOSITION- DEKOSKY et al., "Ginkgo biloba for prevention of dementia - a randomized controlled trial", JAMA, (20081119), vol. 300, no. 19, pages 2253 - 2262, XP055527587
OPPOSITION- E. GYSLING, "Alendronat", pharma-kritik, (19960000), vol. 18, no. 3, pages 9 - 12, XP055528563
OPPOSITION- European Medicines Agency, "European Union herbal monograph on Ginkgo biloba L.", EMA/HMPC/321097/2012, (20150128), pages 1 - 8, XP055306787
OPPOSITION- "Gingium® intens 120", Gebrauchsinformation, (20060600), XP055527542
OPPOSITION- "Ginkgo biloba bei Alzheimer Demenz: Studienlage uneinheitlich", Pressemitteilung IQWiG, (20081121), URL: https://www.iqwig.de/de/presse/pressemitteilungen/2012-oder-frueher/ginkgo-biloba-bei-alzheimer-demenz-studienlage-uneinheitlich.2354.html, XP055527595
OPPOSITION- "Ginkgo biloba bei Alzheimer Demenz: Studienlage uneinheitlich", Pressemitteilung IQWiG, (20081121), XP055527595
OPPOSITION- "Ginkgohaltige Präparate bei Alzheimer Demenz", IQWiG Pressemitteilung, https://www.iqwig.de/de/presse/pressemitteilungen/2012-oder-frueher/ginkgo-biloba-bei-alzheimer-demenz-studienlage-uneinheitlich.2354.html, (20081121), XP055527595
OPPOSITION- HÄNSEL et al., Pharmakognosie - Phytopharmazie, 8. auflage, (20070000), pages 1188 - 1213, 1223-1231, XP055527526
OPPOSITION- HÄNSEL et al., Pharmakognosie - Phytopharmazie; 8. Auflage, (20070000), pages 1188 - 1213, 1223-1231, XP055527526
OPPOSITION- IHL et al., "Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial", Int. J. Geriatr. Psychiatry, (20110000), vol. 2011, no. 26, pages 1186 - 1194, XP055527569
OPPOSITION- IHL et al., "Efficacy and safety of a once-daily formulation of Ginkgo biloba ex- tract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial", Int. J. Geriatr. Psychiatry, (20110000), vol. 26, pages 1186 - 1194, XP055527569
OPPOSITION- IHL et al., "Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial", Int. J. Geriatr. Psychiatry, (20110000), vol. 26, pages 1186 - 1194, XP055527569
OPPOSITION- IHL et al., "Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features; a randomized controlled trial", Int. J. Geriatr. Psychiatry, (20110000), vol. 26, pages 1186 - 1194, XP055527569
OPPOSITION- L. S. SCHNEIDER et al., "A Randomized, Double-Blind, Placebo-Controlled Trial of Two Doses of Ginkgo Biloba Extract in Dementia of the Alzheimer's Type", Current Alzheimer Research, (20050000), vol. 2, pages 541 - 551, XP055306045
OPPOSITION- "Monographie: Trockenextrakt (35-67:1) aus Ginkgo-biloba-Blättern, extrahiert mit Aceton-Wasser", Bundesanzeiger Nr. 133, (19940719), XP055527507
OPPOSITION- P. L. LE BARS et al., "Efficacy and safety of a Ginkgo biloba extract", Public Health Nutrition, (20000000), vol. 3, no. 4A, pages 495 - 499, XP055628981
OPPOSITION- "Rezirkane® 120 mg/240 mg", (20141008), URL: https://compendium.ch/mpro/mnr/25672/html/de, XP055528574
OPPOSITION- RIGNEY et al., "The effects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers", Phytotherapy Research, (19990000), vol. 13, pages 408 - 415, XP055527618
OPPOSITION- RIGNE Y, "The effects of acute doses standardized Gingko biloba extract on memory and psychomotor performance in volunteers", Phytotherapy Research, (19990000), vol. 13, pages 408 - 415, XP055527618
OPPOSITION- RIGNEY U et al., "The effects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers", Phytotherapy Research, (19990000), vol. 13, no. 5, pages 408 - 415, XP055527618
OPPOSITION- SCHNEIDER et al., "A randomized, double-blind, placebo-controlled trial of two dos- es of Ginkgo biloba extract in dementia of the Alzheimers type", Current Alzheimer Research, (20050000), vol. 2, pages 541 - 551, XP055306045
OPPOSITION- SCHNEIDER et al., "A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type", Current Alzheimer Research, (20050000), vol. 2, pages 541 - 551, XP055306045
OPPOSITION- "Tavonin 40 & 120 mg", Product Information, (20061106), pages 1 - 5, XP055527606
OPPOSITION- "Tavonin 40 mg und 120 mg", Fachinformation, (20061106), pages 1 - 5, XP055527606
OPPOSITION- "Tavonin 40 mg und 120 mg", Fachinformation, (20061106), XP055527606
OPPOSITION- "Tebonin® intens 120 mg", Gebrauchsinformation: Information für den Anwender, (20140200), pages 1 - 4, XP055528590
OPPOSITION- T. M. ITIL et al., "The Pharmacological Effects of Ginkgo Biloba, a Plant Extract, On the Brain of Dementia Patients in Comparison With Tacrine", Psychopharmacology Bulletin, (19980000), vol. 34, no. 3, pages 391 - 397, XP055628975
OPPOSITION- V. V. ZAKHAROV et al., "P.5.050 The efficacy of treatment with tanakan (EGb 761) in relation to cognitive impairment in patients with cerebrovascular disease", EUROPEAN NEUROPSYCHOPHARMACOLOGY, (20050000), vol. 15, no. 2, pages S228 - S229, XP027809439
OPPOSITION- GAVRILOVA et al., "Efficacy and safety of Ginkgo biloba extract EGb 761 ® in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial", Int. J. Geriatr. Psychiatry, (20140000), vol. 29, XP055528621
OPPOSITION- KENNEDY et al., "The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers", Psychopharmacology, (20000000), vol. 151, pages 416 - 423, XP055527614
OPPOSITION- JADAD et al., "Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary?", Controlled Clinical Trials, (19960000), vol. 17, pages 1 - 12, XP055528636
OPPOSITION- HERRSCHAFT, HÖRR et al., "Ginkgo biloba extract EGb 761® in dementia with neuropsychiatric features: A randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg", JOURNAL OF PSYCHIATRIC RESEARCH, (20120000), vol. 46, pages 716 - 723, XP028505342
OPPOSITION- CLAXTON et al., "A systematic Review of the Associations Between Dose Regimens and Medication Compliance", Clinical Therapeutics, (20010000), vol. 23, no. 8, pages 1296 - 1310, XP055527623
OPPOSITION- NAPRYEYENKO et al., "Ginkgo biloba special extract in dementia with neuropsychiatric features", Arzneimittel-Forschung, (20070000), vol. 57, no. 1, pages 4 - 11, XP055306047
OPPOSITION- NAPRYEYENKO et al., "Ginkgo biloba special extract in dementia with neuropsychiatric features", Drug Research, (20070000), vol. 57, no. 1, pages 4 - 11, XP055306047
OPPOSITION- O. NAPRYEYEYENKO, "Ginkgo biloba Special Extract in Dementia with Neuropsychiatric Features", Arzneimittel Forschung (Drug Research, (20070000), vol. 57, no. 1, pages 4 - 11, XP055306047
OPPOSITION- KANOWSKI et al., "Ginkgo biloba extract EGb 761 in Dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial", Pharmacopsychiatry, (20030000), vol. 36, pages 297 - 303, XP003025475
OPPOSITION- TURNER et al., "Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy", The New England Journal of Medicine, (20080000), vol. 358, pages 252 - 260, XP055528643
OPPOSITION- T. M. ITIL et al., "Central Nervous System Effects of Ginkgo Biloba, a Plant Extract", American Journal of Therapeutics, (19960000), vol. 3, pages 63 - 73, XP055306041
OPPOSITION- GRASS-KAPANKE et al., "Effects of Ginkgo Biloba Special Extract EGb 761® in Very Mild Cognitive Impairment (vMCI)", Neuroscience & Medicine, (20110000), vol. 2, pages 48 - 56, XP055528611
OTHER- "Chapter 1 Marketing authorisation", European Commission, Procedures for marketing authorisation, (20051100), vol. 2A, pages 1 - 46, XP055306430
OTHER- "Demenz", Christoph Zink, Pschyrembel Klinisches Wörterbuch, 256 Auflage, Walter de Gruyter, (19900000), page 335, XP055278121
OTHER- "EudraCT Number: 2005-003747-31", Clinical Trials Register UE, (20051227), pages 1 - 7, URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-003747-31, XP055307027
OTHER- "EudraCT Number: 2005-005765-11", Clinical Trials Register EU, (20060314), pages 1 - 8, URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005765-11, XP055307030
OTHER- European Medicines Agency, "European Union herbal monograph on Ginkgo biloba L., folium", EMA/HMPC/321097/2012, (20150128), pages 1 - 8, XP055306787
OTHER- Kunststoff-Handbuch, Carl Hanser Verlag, (19630000), vol. II, page 50
OTHER- SCHNEIDER et al., "A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type", Current Alzheimer Research, (20051200), vol. 2, no. 5, pages 541 - 551, XP055306045
OTHER- NAPRYEYENKO O. et al., "Ginkgo biloba Special Extract in Dementia with Neuropsychiatric Features", Drug Research, (20070000), vol. 57, no. 1, pages 4 - 11, XP055306047
OTHER- ITIL et al., "CENTRAL NERVOUS SYSTEM EFFECTS OF GINKGOBILOBA, A PLANT EXTRACT", American Journal of Therapeutics, (19960100), vol. 3, no. 1, pages 63 - 73, XP055306041
OTHER- GAUTHIER et al., "Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials", Clinical Interventions in Aging, (20140000), vol. 9, pages 2065 - 2077, XP055306056
SEARCH- ANDREY SCRIPNIKOV ET AL, "Effects of Ginkgo biloba Extract EGb 761 on neuropsychiatric symptoms of dementia: findings from a randomised controlled trial", WIENER MEDIZINISCHE WOCHENSCHRIFT, (200707), vol. 157, no. 13-14, pages 295 - 300, XP002480016 [X] 1-19 * abstract * * page 296, column R, line 19 - line 31 *
SEARCH- MARTIEN VAN DONGEN ET AL, "Ginkgo for elderly people with dementia and age-associated memmory impairment: a randomized clinical trial", JOURNAL OF CLINICAL EPIDEMIOLOGY, (2003), vol. 56, pages 367 - 376, XP002480015 [A] 1-21 * abstract * * page 369, column R, paragraph 2.3 - page 370, column L *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents